Monocyte chemoattractant protein 1 (MCP1) with recruiting monocytes is an important factor at the beginning of inflammatory disorders such as atherosclerosis which seems its blocking preclude this process and help improvement of related diseases. To perform clinical research in this field, MCP1 protein is required but firstly, animal studies should be done. As the rabbit is a suitable model for many inflammatory disorders, and Escherichia coli BL21(DE3) (BL21) cell is a high-efficiency host for protein expression, we decided to produce recombinant rabbit MCP1 (rRMCP1) in BL21/pET28a system. After codon usage, a construct containing RMCP1 sequence was synthesized, cloned into the pET28a plasmid, and overexpressed in BL21 cells. Followed that, with changing expression condition such as cell concentration before the induction, time period, temperature, shaking rate and inducer concentration (IPTG), rRMCP1 expression was optimized, and purified by Ni-NTA. The biological activity of the expressed protein was verified using monocyte migration assay. Using this expression system, nearly 28 mg/mL rRMCP1 was produced at 26
INTRODUCTION
Chemokines are cytokines that participate in inflammation by recruiting leukocytes (Nathan 2002) . The leukocytes are actively involved in the clearance of infectious agents and dead cells at the inflammation site, but may be also contributed in the pathology of inflammatory disorders, such as the development of atherosclerotic lesions (Nathan 2002) . Therefore, inhibition of leukocyte traffic to the inflammation site is considered as an effective approach for the prevention and control of inflammation. This may be achieved through blocking the involved molecules by monoclonal antibodies, soluble receptors, and recently, aptamers. Numerous chemotactic factors play role in leukocyte recruitment. Monocyte chemoattractant protein 1 (MCP1) belongs to CC-type chemokines, key cytokines that accelerate the recruitment of monocytes to inflammation sites (Deshmane et al. 2009 ). This chemokine has been detected at inflammation sites, in the human endothelial and smooth muscle cells, and even in rabbit atherosclerotic lesions (Nelken et al. 1991; Yla-Herttuala et al. 1991; Rayner et al. 2000) . The abundance of MCP1 at atherosclerotic lesions may suggest its crucial role in the initiation, formation, and development of atherosclerosis. Moreover, the results of many animal studies suggest that MCP1 may play a pivotal role in many inflammatory disorders, e.g. intra-aneurysm tissue and diabetic wounds (Wood et al. 2014) . Therefore, trapping of MCP1 by various biomolecules could be an effective approach for the treatment or prevention of these diseases.
In this regard, intense researches have been done to generate monoclonal or polyclonal antibodies, nanobodies, and aptamers against this peptide, and yet, an antibody (MCP1 monoclonal antibody, cat no. 29H86L56, Thermo Fisher Scientific) and a Spiegelmer (mNOX-E36) against human MCP1 have indeed been generated (Rhodes et al. 2001) . For doing such projects, purified MCP1 protein with sufficient amount is necessary. Moreover, for clinical use of the new biological therapeutic agents, they should be tested in animal studies, which the animal origin of each antigen has to be existed. Since the rabbit is an appropriate animal model for atherosclerosis (Kapourchali et al. 2014) , production of rabbit MCP1 (RMCP1) is a good strategy for boosting future atherosclerosis research.
Many systems are available for the production of heterologous proteins, including bacterial (e.g. the Gram-negative bacterium Escherichia coli (E. Coli)), yeast (e.g. Pichia pastoris) and baculovirus systems, mammalian cell lines and Dictyostelium discoideum (Rai and Padh 2001; Tate et al. 2003) . The major objective of using these systems is high protein yield. Because of the low cost and fast growth of the host, high copy number, and availability of mutant host strains, E. coli is considered as one of the best systems for a rapid and economic production of high yields of recombinant proteins (Jana and Deb 2005) , although low or no expression of some eukaryotic proteins is the major limitation of this system (Jana and Deb 2005; Structural Genomics et al. 2008 ). In the current study, we generated recombinant RMCP1 (rRMCP1) in an optimized E. coli system and verified its activity in vitro.
MATERIALS AND METHODS

Plasmid construction, cloning, and E. coli transformation
After codon usage analysis, a 320 bp-long construct containing codon-optimized RMCP1 gene sequence (NM 001082294.1) flanked by two restriction sites, NcoI and XhoI in pUC57 (RMCP1/pUC57), was generated by GeneCust (Dudelange, Luxembourg) (Fig. 1 ). RMCP1/pUC57 was then used to transform E. coli TOP10F' strain (TOP10) cells to amplify the plasmid DNA. The cells were grown in Luria-Bertani (LB) broth (SigmaAldrich, St. Louis, MO) containing tetracycline (10 μg/mL) at 37
• C and 200 rpm. The plasmid was then extracted using the SolGent Plasmid Mini Prep kit, according to the manufacturer's instructions (Seoul, Korea), and digested with XhoI and NcoI.
The digestion products were separated on agarose gel and the 
Recombinant protein expression
The constructed plasmid (RMCP1/pET28a) was extracted from positive clones and used to transform E. coli BL21 (DE3) (BL21) (Pasteur Institute). Single transformants were selected on LB agar (Sigma-Aldrich) containing 25 μg/mL of kanamycin, and verified by colony PCR and XhoI/NcoI restriction enzyme digestion. The exact sequence of the inserted fragment in the resultant clones (two clones) was confirmed by DNA sequencing, which was performed by Bioneer Company (Korea). The two positive clones (clones 2 and 3) were selected for rRMCP1 protein production. To induce protein expression, the clones were cultured in LB broth supplemented with 25 μg/mL of kanamycin, with isopropyl-β-d-1-thiogalactopyranoside (IPTG) induction. To determine the optimal conditions allowing an intermediate level of protein expression, the following induction parameters were investigated: OD 600 of bacterial culture at induction (0.4-0.5, 1.0-1.2 and 2.0-2.5), temperature (26
30
• C and 37 • C), induction duration (5-24 h), shaking rate (180-250 rpm) and final concentration of IPTG (0.5, 1 and 2 mM). The effect of media replacement every 4-6 h during induction was also investigated; namely, every 4-6 h, the bacteria were collected by centrifugation and fresh culture medium with the same antibiotic and IPTG concentrations was added. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with protein visualization by Coomassie Brilliant Blue R-250 staining and western blotting with conjugated horseradish peroxidase/anti-His antibody (Thermo Scientific) was performed to verify the expression of rRMCP1.
Recombinant protein purification
BL21 cells producing the rRMCP1 protein were lysed in 4 mL of lysis buffer [100 mM NaH 2 PO 4 , 10 mM Tris-HCl (pH 8.0) and 8 M urea] per 1 g of bacterial pellet, and this process was completed by sonication (five pulses of 50 s), according to QIAGEN (Hilden, Germany) protein purification protocol. The lysates were centrifuged at 8500 × g at 4
• C for 3 min, and the supernatant was then incubated with Nickel-nitrilotriacetic acid (Ni-NTA) resin (QIAGEN) at room temperature (22
• C) for 45 min. The protein/resin complex was applied to a miniature QIAGEN column, washed, and eluted using buffers B to E; and the fractions were separately collected. Following SDS-PAGE analysis of the collected fractions, the purified protein fractions were pooled and concentrated using Amicon Ultra-4 centrifugal filters (Merck Millipore, Billerica, MA). Protein concentration was determined using the Bradford assay (Bradford 1976) , with bovine serum albumin (Sigma-Aldrich) as a standard.
SDS-PAGE and western blotting
SDS-PAGE BL21, BL21/pET28a and BL21/pET28a/RMCP1 cells were cultured in LB broth medium. At OD 600 = 0.4-0.5, BL21/pET28a/RMCP1 culture was split into two tubes, and one half was induced by IPTG for 24 h. Samples were withdrawn 5, 16 and 24 h after induction and the amount of bacteria was normalized between the three conditions by measuring their OD 600 s and equaling them by dilution, and prepared for electrophoresis. The samples and a pre-stained protein marker (10-270 kDa, Thermo Scientific) were loaded onto a 15% SDS-PAGE gel, then stained in a Coomassie R-250 solution, for 3 h, and destained.
Western blotting
Following SDS-PAGE, the proteins were transferred to a polyvinylidene difluoride membrane using transfer buffer (25 mM Tris base, 190 mM glycine, 20% methanol, pH 8.3), at 90 V for 90 min. (Feizollahzadeh et al. 2016) . The rRMCP1 protein was detected using mouse monoclonal anti-poly-histidine peroxidase conjugated antibody (working dilution of 1:2000; Sigma-Aldrich).
Biological activity of rRMCP1
Monocyte culture Nearly 3 mL blood from ears of two male New Zealand white rabbits (2.3 ± 0.2 kg) (purchased from Pasteur Institute) was taken. The experiment was approved by the animal ethics committee of Isfahan University of Medical Sciences, Isfahan, Iran. The monocytes were separated by Ficoll-Paque (SigmaAldrich) according to the manufacturer's recommendations. The separated monocytes were maintained in Roswell Park Memorial Institute medium (RPMI) (Biosera, Nuaille, France) supplemented with 10% of fetal bovine serum (Sigma-Aldrich), 100 U/mL of penicillin and 100 μg/mL of streptomycin (Invitrogen, Carlsbad, CA), in a humid incubator at an atmosphere of 5% CO 2 at 37
• C.
rRMCP1-mediated monocyte migration assay
Two six-well cells with a 0.4-μm pore polycarbonate (PCTE) membrane (Sterlitech Corporation, Kent, OH) were used. Different concentrations of purified rRMCP1 (5, 10, 15 or 20 μg per 2 mL of RPMI medium supplemented with 0.5% of fetal bovine serum, 100 U/mL of penicillin and 100 μg/mL of streptomycin) were prepared, and placed in the bottom chamber of each well, in duplicate. Two wells were the controls, with no protein added. Monocytes (2.5 × 10 6 cells) were suspended in 10 mL of RPMI, and 1 mL of the suspension was placed in the top chamber. The plates were then incubated at 37
• C in a humid incubator, 5% CO 2 , overnight. The media in the top chambers were transferred to separate tubes. The media from the bottom chambers were transferred to separate tubes, centrifuged at 1500 × g for 5 min at room temperature, the pellets suspended in 1 mL of RPMI and the cells counted after trypan blue staining. The 
Statistical analysis
The data of monocyte migration assay were analyzed in IBM SPSS software (version 20.0) using the independent t test and one-way ANOVA. P-values lower than 0.05 were considered significant.
RESULTS
RMCP1/pET28a plasmid cloning and sequencing
Transformation efficiency of BL21 cells with the RMCP1/pET28a plasmid was more than 65%. Agarose gel electrophoresis of PCR products from colony PCR with selected BL21/RMCP1/pET28a clones revealed a ca. 500 bp band and confirmed the cloning of RMCP1 fragment into the pET28a (Fig. 2a) . The length of RMCP1-coding sequence cloned into pET28a vector was 308 bp. After digestion of the RMCP1/pET28a expression plasmid with XhoI and NcoI, a 314-bp fragment containing the RMCP1 sequence was released (Fig. 2b) . DNA sequencing using T7 primers further confirmed that there were no mutations in the sequence cloned into the pET28a plasmid (data not shown).
Protein expression
The optimum conditions for rRMCP1 expression in BL21 were determined by testing different experimental parameters (see Materials and Methods section). The optimal conditions were as follows: induction of protein synthesis in bacterial cultures at OD 600 = 0.4, induction with 1 mM IPTG and induction in an incubator shaker at 26
• C, 180 rpm, for 24 h. The appearance of a ca.
12.7 kDa band on SDS-PAGE gels ( Fig. 3a) and after western blotting ( Fig. 3b ) confirmed the expression of rRMCP1. The SDS-PAGE and western blot analysis of different fractions obtained during rRMCP1 purification on Ni-NTA resin are presented in Fig. 4 . The purification yield was 28 mg protein per 1 L of bacterial culture.
Biological activity of rRMCP1
The monocyte migration assay revealed a significant chemotactic effect of rRMCP1, compared with control (P < 0.001) (Fig. 5) .
The effect was protein concentration-dependent (P < 0.05).
DISCUSSION
In the current study, we succeed to express and purify an intermediate level of rRMCP1. This protein level was obtained by optimizing some affecting factors. Before RMCP1 construct synthesis, codon usage was done, because various organisms have different codon preference, and U/mL of penicillin and 100 μg/mL of streptomycin were placed in the top chamber of each polycarbonate (PCTE) membrane well. The given concentrations of purified rRMCP1 in 2 mL of RPMI were placed in the bottom chamber of each well and incubated at 37
• C in a humid incubator, 5% CO2, overnight. Each concentration was tested in duplicate. Two wells were the controls, with no protein. P value of one-way ANOVA was less than 0.05. most codons used in mammalian cells are rarely recognized in bacterial systems (Sørensen, Kurland and Pedersen 1989) . Another major factor affecting recombinant protein yield is the heterologous host. Because of more compatible with eukaryotic proteins, easy growth, simple manipulation, inexpensive expression process, well-defined genetic and physiology, rapid and high-expression yield of eukaryotic proteins, and availability of several vectors for high-level expression, E. coli was selected the host in the current study (Stormo, Schneider and Gold 1982; Crowl et al. 1985; Devasahayam 2007) .
Moreover, the frequency of expression vector that is used to transform the host cell plays an important role in protein expression (Sørensen, Kurland and Pedersen 1989) . We used the high-copy-number pET28a plasmid with f1 pBR322 replication origin, which is considered as one of the most powerful origins of replication and a strong T7 promoter. This is one of the most commonly used protein expression systems, where bacteriophage T7 RNA polymerase, produced by a DE3 lysogen in the host bacteria, BL21 (DE3), drives the transcription of the target gene from the expression vector (George, Brosh and Matson 1994; Studier 2005 ).
Other factors, e.g. the concentration of the inducer of protein expression, also affect the yield of the recombinant protein. In the system used in the current study, the expression of the target gene is regulated by IPTG-inducible lac UV5 promoter (George, Brosh and Matson 1994; Studier 2005) . The expression of rRMCP1 was similar after induction with 1 and 2 mM IPTG. Some researchers reported that higher IPTG concentration leads to recombinant protein aggregation (Jhamb and Sahoo 2012) . The effect of IPTG concentration on protein yield depends on protein type; if the expressed protein is toxic or has a tendency to aggregate at higher concentrations, the expression should be induced with lower IPTG concentration (Tomoyasu et al. 2001) .
To achieve intermediate to high expression of a recombinant protein (on the scale of mg per 1 L of cell culture), culture conditions, such as culture media, cell density before induction, duration of induction, temperature during induction, shaking rate and concentration of the antibiotic used, have to be optimized (Ren et al. 2009 ). The highest level of rRMCP1 protein expression was obtained at a cell density of 0.4-0.5, and was not considerable at higher cell densities. San-Miguel, Pérez-Bermúdez and Gavidia (2013) succeeded in producing soluble eukaryotic recombinant proteins in early-phase cultures of BL21 (DE3) (OD 600 = 0.1) at low temperature (4
• C), and with protein expression nearly four times higher than in the mild-log phase cultures (OD 600 = 0.6). They concluded that under these conditions, the expression of the target protein increases while the expression of endogenous bacterial proteins declines, leading to a more efficient purification process of the recombinant protein (San-Miguel, Pérez-Bermúdez and Gavidia 2013).
To check the effect of temperature after induction on the expression of rRMCP1, different temperatures were tested and the highest protein concentration was obtained at 26
• C. Latifi et al. (2015) tested the expression of organophosphorus hydrolase from Pseudomonas diminuta (UniProt: accession no. P0A434) in BL21 at induction OD 600 = 0.7, at 18
• C, 30
• C and 37
• C, overnight.
Similar to our findings, they observed that more total protein was produced at lower temperatures. Bacterial growth is reduced at lower temperatures, allowing sufficient time for protein folding. In addition, mRNA and protein stability are increased at low temperatures (Doelle, Rokem and Berovic 2009) . Furthermore, the activity of proteolytic enzymes decreases at lower temperatures and, therefore, the rate of cell lysis or proteolysis is reduced (Peterson et al. 2007) . Moreover, lowering the temperature at the time of induction reduces the toxicity of the expressed protein (Baneyx and Mujacic 2004) . Another factor, whose effect studied, was the culture agitation rate during protein expression (180, 220 and 250 rpm). The best protein yield was obtained at 180 rpm. This could be because of slower bacterial growth, and hence better protein folding, similar to the effect of lower temperature.
We found that the duration of induction affects the rRMCP1 yield. Namely, with increasing induction time (from 4 to 24 h), the protein yield was elevated. This suggested that rRMCP1 is a non-toxic protein, and over time, cell division, growth and protein expression would continue.
Increasing the cell density after completing the recombinant protein expression is the most important factor in the protein yield enhancement. The culture conditions and growth medium are the main determinants of cell density, and therefore, with increasing culture volume, cell density will increase (Kram and Finkel 2014) . In our study, 28 mg of rRMCP1 was obtained from 1 L of culture. Under physiological conditions, a standard growth medium, such as LB broth, can support E. coli culture density up to OD600 of 2.0-3.0; a relatively enriched medium, e.g. Terrific Broth (TB), allows the E. coli culture to achieve OD600 of 10-20 at the end of protein expression induction (Sivashanmugam et al. 2009 ). In the current study, LB broth was used and culture OD 600 following 24-h induction reached nearly 3.0.
During and following translation, correct folding of the expressed proteins is crucial for a stable and biologically active product, increasing the yield (Thomas and Baneyx 1996) . Here, the biological activity of the expressed protein was verified by the monocyte migration assay.
Several therapeutic heterologous proteins have been successfully expressed in E. coli. The first one was human insulin, approved for human use in 1982, in UK, West Germany, the Netherlands and the USA (Crowl et al. 1985) . The highest expression of an active mutated Anabaena variabilis phenylalanine ammonia lyase has been obtained with 0.5 mM IPTG induction in TB medium at 25
• C, 150 rpm, 18 h, in pET/BL21 system similar to the one used in the current study (Jaliani et al. 2014) . Hu et al. (2015) succeeded in optimizing and obtaining the highest soluble PTEN protein yields in a pGEX-6p-1/BL21 system with pBR322 replication origin at OD 600 of 0.6-0.8, with 0.1 M IPTG induction for 8 h at 20
• C. In another study, high-yield expression of human chemokine receptors (hCRs) was attained at OD 600 of 0.6, 16
• C for 24 h, with 0.3 mM IPTG induction from pEXP-hCRs in E.
coli C41(DE3), and 0.05% l-arabinose from pBAD-hCRs in TOP10 (Ren et al. 2009 ). As reported in another study, the highest specific yield of a soluble form of cHSPA6 was produced with 10 μM IPTG induction at 37 • C for 3 h (Malik et al. 2016) .
In addition to the above factors, amino acid sequence and codons encoding the N-terminus of the target protein (ShakiLoewenstein et al. 2005) , changing 5'-end GC content of target protein (Rao et al. 2013) , co-expression with chaperones or fusion tags (Baneyx and Mujacic 2004) , and directing to subcellular compartments or locations (Nair and Rost 2003) are other standard techniques that may be utilized in most molecular biology laboratories to optimize protein yield. For instance, Lee, Kwon and Huh (2015) were able to express recombinant human MCP1 using a pET SUMO (small ubiquitin-like modifier) vector in BL21. In this system, SUMO as a fusion tag for MCP1 increased yield of the expressed protein. It is possible that these approaches might result in higher yields of rRMCP1 but they have not been investigated in the current study.
CONCLUSION
In the current study, we expressed rRMCP1 in the E. coli-pET28a expression system. The expression of the recombinant protein was optimized by a combination of codon usage, changing the inducer concentration, medium volume, the optical density of bacterial culture before induction, duration of induction, induction temperature and culture agitation. Monocyte migration test verified the dose-dependent biological activity of expressing rRMCP1.
As RMCP1 is an expensive protein that could limit its use, its production could help researchers to fulfill their novel ideas especially in the inflammation field without any worry.
It is suggested that other factors, such as the type of the growth medium, fusing sequence of special proteins to intended protein sequence, and utilization of molecular chaperones, have to be optimized to achieve even higher yields of rRMCP1 protein.
